Few UK "Promising Innovative Medicine" Holders Seek Joint MHRA/NICE Advice – Rawlins
Executive Summary
MHRA chief says too few drug makers granted PIM designation on the basis of early clinical data are making use of joint consultations with the agency and the cost-effectiveness watchdog NICE.